MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Home・Aandelen Lijst・Pulmatrix Inc

Pulmatrix Inc

Gesloten

1.2 2.56

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.1

Max

1.23

Belangrijke statistieken
By Trading Economics
Inkomsten	-51K -928K
EPS	-0.254
Werknemers	2
EBITDA	-51K -928K

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-6.6M 4.8M
Vorige openingsprijs	-1.36
Vorige sluitingsprijs	1.2

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 apr 2026, 23:25 UTC

Belangrijke Nieuwsgebeurtenissen

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 apr 2026, 22:45 UTC

Belangrijke Nieuwsgebeurtenissen

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 apr 2026, 18:03 UTC

Winsten

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 apr 2026, 23:58 UTC

Winsten

Review & Preview: Earnings Time -- Barrons.com

13 apr 2026, 23:49 UTC

Marktinformatie

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 apr 2026, 23:33 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 apr 2026, 23:20 UTC

Marktinformatie

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 apr 2026, 23:01 UTC

Winsten

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 apr 2026, 23:01 UTC

Winsten

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 apr 2026, 23:01 UTC

Winsten

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 apr 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 apr 2026, 21:26 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 apr 2026, 21:23 UTC

Winsten

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 apr 2026, 21:16 UTC

Winsten

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

13 apr 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

13 apr 2026, 20:34 UTC

Winsten

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 apr 2026, 20:34 UTC

Winsten

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 apr 2026, 20:34 UTC

Winsten

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 apr 2026, 19:59 UTC

Marktinformatie

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 apr 2026, 19:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 apr 2026, 19:27 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Correction to Precious Metals Market Talk on April 9

13 apr 2026, 19:14 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 apr 2026, 18:59 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 apr 2026, 18:59 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 apr 2026, 18:43 UTC

Marktinformatie

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pulmatrix Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.